For instance, CV9202combined with hypo-fractionated radiotherapy induced multiantigenT-cell responses and lung cancer control in nearly half of patients. Likewise, early data on vaccines plus anti-PD-1/-PD-L1(e.g., cemiplimab, durvalumab, tremelimumab) show higher responserates than vaccine alone. These findingssuggest future lung cancer vaccines should be given in combinationregimens or with built-in adjuvants. The gene discussed is PDCD1; the disease is lung cancer.